Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 86Leukemia 50Gastrointestinal Stromal Tumors 41Leukemia, Myeloid, Chronic-Phase 28Precursor Cell Lymphoblastic Leukemia-Lymphoma 25Blast Crisis 17Philadelphia Chromosome 13Brain Neoplasms 12Sarcoma 10Leukemia, Myeloid, Acute 10Glioblastoma 10Lung Neoplasms 9Leukemia, Myeloid, Accelerated Phase 9Gliosarcoma 9Prostatic Neoplasms 8Neoplasms 7Neoplasm Metastasis 7Glioma 7Oligodendroglioma 6Melanoma 6Leukemia, Myelomonocytic, Chronic 6Dermatofibrosarcoma 6Astrocytoma 6Small Cell Lung Carcinoma 5Recurrence 5Primary Myelofibrosis 5Polycythemia Vera 5Ovarian Neoplasms 5Leukemia, Myeloid 5Central Nervous System Neoplasms 5

Interventions

ripretinib 1Imatinib Mesylate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Mast Cell Activation Disorders × Imatinib Mesylate × Clear all
NCT01297777 2016-08-29

Imatinib in KIT-negative Systemic Mastocytosis

Hospital Virgen de la Salud

Phase 4 Completed
10 enrolled
Myeloid

Mast Cell Activation Disorders, Mastocytosis, Mastocytosis, Systemic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡